B

Bruker

Manufactures analytical instruments for NMR diagnostics

Field Microbiology Sales Coordinator

Full-TimeDeadline 9/22/27
No salary listed
Junior
Bachelor's, PhD
Mexico City, CDMX, Mexico
HybridTravel extensively, up to 70%, with occasional weekend travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • Solid understanding of microbiology workflows and technologies.
  • Familiarity with hospital labs, private diagnostics providers, or food/pharma quality labs in Latin America.
  • At least 2 years of experience in a commercial, technical sales, or customer-facing role within the diagnostics or life sciences industry.
  • Ability to promote company products and services to varied prospects and customers and secure sales commitments.
  • Verbal, written, and technical presentation skills, including advanced Excel proficiency.
  • Experience with customer relationship management platforms.
  • Self-motivation and willingness to take ownership of projects assigned by the management team.
  • Willingness to travel extensively, up to 70%, and maintain a current passport and U.S. visa as required for international travel; occasional weekend travel is required.
  • Proficiency in English and Spanish.
  • Bachelor’s degree in a related life sciences or health-related field.
  • Computer skills in Excel, PowerPoint, Teams, Outlook, and Salesforce or another customer relationship management tool.
Responsibilities
  • Execute territory strategies to identify, prospect, and capture new business opportunities across clinical, food, pharmaceutical, and academic markets.
  • Conduct on-site and virtual customer visits to build relationships, identify needs, and generate new sales opportunities.
  • Collaborate with Regional Sales Managers and Sales Specialists to advance qualified leads through the sales funnel.
  • Lead early-stage commercial discussions, organize technical presentations, and coordinate product evaluations.
  • Manage and maintain an accurate sales pipeline using customer relationship management tools, ensuring timely follow-up and opportunity progression.
  • Support strategic marketing activities, including local events, webinars, and customer engagement campaigns.
  • Support TPAs in the assigned territory to increase sales of instruments in clinical, food and beverage, agriculture, pharmaceutical, and research markets.
  • Follow company expense-control policies and stay within meeting expense budgets.
  • Plan and execute individual travel within travel guidelines and expense budget objectives.
Desired Qualifications
  • Familiarity with MALDI-TOF.
  • PhD.
  • Previous experience in microbiology.

About the company

Bruker makes analytical and diagnostic instruments used by researchers and industries. Its products help analyze materials and biological samples to reveal chemical structure, composition, and properties, with notable roots in nuclear magnetic resonance (NMR) technology and a broad portfolio beyond that field. The company works by designing and selling instruments such as analytical tools that collect data from samples (for example, signals from nuclei in NMR or other spectroscopic methods) and provide insights to researchers. Bruker differentiates itself through a long history of developing advanced technologies, a focus on innovation in scientific instrumentation, and a global product range serving life sciences, materials science, and environmental analysis, supported by steady investment in research and development. Its goal is to equip researchers and industries with reliable tools to push the boundaries of what is possible in science and discovery.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Billerica, Massachusetts

Founded

1960

Get referred to Bruker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 28, 2026 timsUltra AIP and timsOmni launches deepen proteomics and oligonucleotide workflows.
  • August 10, 2026 MIMETAS deal expands Bruker into human-relevant drug discovery models.
  • UC Berkeley ordered over $6 million of Bruker NMR systems, delivering 2027 revenue.

What critics are saying

  • Bruker’s first-half 2026 organic revenue declined 0.8%, exposing fragile demand recovery.
  • Academic spending stayed soft in 2026, while tariffs and currency pressured results.
  • If MIMETAS and fusion remain niche, Bruker’s acquisition-heavy strategy destroys capital returns.

What makes Bruker unique

  • Bruker owns timsTOF proteomics, NMR, microscopy, and microphysiological systems under one platform.
  • Bruker’s August 31 XFlash 7200 FIRE raises SEM-EDS throughput beyond conventional detector designs.
  • Bruker’s BEST superconductors supply ITER, Wendelstein 7-X, CERN, and fusion demonstrators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Disability Insurance
  • Life Insurance
  • Dental Insurance
  • Flexible Work Hours
  • Employee Discounts

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

13%

2 year growth

13%
Business Wire
Oct 14th, 2026
Bruker Completes Acquisition of PhenomeX

Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools...

Financial Times
Sep 28th, 2026
Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research.

Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research. Sep 28 2026 12:00 BST * MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP * ProteoScape connects PASEF discovery with rapid prm-PASEF target validation * Spectronaut(R) AI transfer learning accelerates adaptation to new MS capabilities * Guided PASEF EXciD enables high-throughput glycopeptide characterization * Integrated HDX-MS workflows advance protein conformation and interaction studies * timsOmni(TM) enables RNA and DNA top-down structural and native RNA analysis SINGAPORE-(BUSINESS WIRE)-Sep. 28, 2026- At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF discovery with prm-PASEF target validation on the same timsTOF platform. Novel timsOmni and integrated HDX-MS workflows extend structural analysis to glycopeptides, proteins, and nucleic acids.

MarketScreener
Sep 21st, 2026
Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure.

Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure. Published on 09/21/2026 at 09:36 am EDT S&P Capital IQ Bruker Corporation announced a multi-system order from University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz?class instrumentation. The investment is centered on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, complemented by several additional NMR systems and upgrades supporting solid-state, solution-state and Dynamic Nuclear Polarization (DNP) research. The UC Berkeley NMR order exceeds USD 6 million and is expected to be delivered in 2027. (C) S&P Capital IQ - 2026

U.S. Securities and Exchange Commission
Sep 19th, 2026
10-K

Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

U.S. Securities and Exchange Commission
Sep 18th, 2026
10-Q

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023